Evia Bio

Executive Summary

Evia Bio is a Boston-based life science innovation company specializing in advanced cryopreservation solutions for the cell therapy market. Founded in 2020, the company leverages AI-driven formulation and non-toxic, organic cryoprotectants to significantly improve cell viability and patient safety compared to conventional DMSO-based methods. Its flagship product, CellShield™, alongside custom development services and educational programs, aims to address critical bottlenecks in cell therapy manufacturing and storage. By eliminating toxic cryoprotectants and optimizing preservation protocols through machine learning, Evia Bio enhances post-thaw recovery and functional integrity of therapeutic cells, enabling more effective and accessible cell therapies. The cell therapy market is rapidly expanding, with increasing demand for reliable cryopreservation to support supply chain logistics and patient dosing. Evia Bio’s technology offers a compelling value proposition to developers seeking safer, more efficient preservation solutions. With a focus on innovation and customer collaboration, the company is well-positioned to capture market share as regulatory and clinical needs evolve. While still in early commercialization, Evia Bio’s unique approach and strong intellectual property moat provide a solid foundation for growth. The company is likely to seek strategic partnerships and additional funding to scale operations and accelerate adoption.

Upcoming Catalysts (preview)

• Q2 2026Commercial launch of CellShield™ with initial customer adoptions80% success
• Q3 2026Strategic partnership with a leading cell therapy developer50% success
• Q4 2026Series A financing round to support scale-up and R&D60% success